Could a cholesterol drug boost immunotherapy in lung cancer?
NCT ID NCT05144529
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding evolocumab (a cholesterol-lowering drug) to standard immunotherapy (nivolumab and ipilimumab) is safe and helps the immune system fight advanced non-small cell lung cancer. It included 19 people with newly diagnosed metastatic lung cancer who had not received prior treatment. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Univ. Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a Two-Drug combo outsmart resistant lung cancer?
- Can a new drug shrink Hard-to-Treat tumors?
- Can zapping a few spots keep lung cancer in check?
- Could a lighter immunotherapy schedule keep advanced cancers in check?